Liminatus Pharma, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Chris Kim (CEO) and Scott Dam (CFO) have signed standard Sarbanes-Oxley Section 302 and 906 certifications for the quarterly period ended June 30, 2026, attesting to the accuracy of financial statements and the effectiveness of disclosure controls and internal financial reporting procedures as of August 14, 2026. No material weaknesses, deficiencies, or fraud involving management were disclosed.
Why this rating
Routine executive certification required by law; no substantive business event, material weakness, or control deficiency disclosed. Standard quarterly filing.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.